Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Here’s what’s in store this year for new hepatitis C therapies, as well as approvals for new uses of existing treatments.
Merck’s investigational hepatitis C treatment grazoprevir/elbasvir cured high rates of the virus among individuals coinfected with HIV.
Highlights from presentations at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in San Francisco.
In recent trials Harvoni, Viekira Pak and grazoprevir/elbasvir all cured high rates of hepatitis C among those coinfected with HIV.
Merck has filed a new drug application with the U.S. Food and Drug Administration (FDA) for approval of its single-tablet hepatitis C...
Highlights from the 50th Annual Meeting of the European Association for the Study of the Liver.
Merck’s grazoprevir/elbasvir, given with or without ribavirin, cured over 90 percent of various subgroups of people with hepatitis C, includin...
Twelve or 18 weeks of Merck’s grazoprevir/elbasvir, with or without ribavirin, cured 91 to 100 percent of hard-to-treat people with genotype 1...
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.